We are live on ! Find out more
TARO

Taro Pharmaceutical Industries Ltd.

Delisted

TARO was delisted on the 21st of June, 2024.

82 hedge funds and large institutions have $185M invested in Taro Pharmaceutical Industries Ltd. in 2023 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

15% more funds holding

Funds holding: 7182 (+11)

0% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 23

1% less capital invested

Capital invested by funds: $186M → $185M (-$1.41M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
82
Holders Change
+11
Holders Change %
+15.49%
% of All Funds
1.3%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
20
Increased
23
Reduced
23
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$668K +$302K +8,044 +83%
AIIMS
27
Analyst IMS Investment Management Services
Israel
$513K
Two Sigma Advisers
28
Two Sigma Advisers
New York
$491K +$488K +13,013 New
CS
29
Credit Suisse
Switzerland
$439K -$18.8K -502 -4%
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$435K -$34.4K -916 -7%
Connor, Clark & Lunn Investment Management (CC&L)
31
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$427K +$425K +11,333 New
Bank of America
32
Bank of America
North Carolina
$417K +$100K +2,671 +32%
MAM
33
Martingale Asset Management
Massachusetts
$414K +$412K +10,988 New
IA
34
Inspire Advisors
Idaho
$403K -$97.7K -2,603 -20%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$376K -$904K -24,088 -71%
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$368K +$15.7K +419 +4%
Legal & General Group
37
Legal & General Group
United Kingdom
$312K -$3.94K -105 -1%
AGM
38
Alpine Global Management
New York
$308K +$306K +8,158 New
WG
39
Winton Group
United Kingdom
$269K +$268K +7,145 New
HM
40
Harvest Management
New York
$268K +$41.5K +1,106 +18%
MGP
41
Metis Global Partners
California
$262K +$260K +6,938 New
SSA
42
Schonfeld Strategic Advisors
New York
$245K +$244K +6,500 New
JP Morgan Chase
43
JP Morgan Chase
New York
$242K -$11.4K -305 -5%
Deutsche Bank
44
Deutsche Bank
Germany
$238K +$25.8K +687 +12%
VI
45
Vestcor Inc
New Brunswick, Canada
$222K
Cetera Investment Advisers
46
Cetera Investment Advisers
Illinois
$216K
DAM
47
DLD Asset Management
New York
$215K +$214K +5,708 New
UBS AM
48
UBS AM
Illinois
$207K +$206K +5,494 New
Barclays
49
Barclays
United Kingdom
$182K -$6.76K -180 -4%
AIG
50
American International Group
New York
$154K +$5.44K +145 +4%

TARO Hedge Fund Activity: Q3 2023 in Review

82 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q3 2023, worth a combined $185M — down 0.76% from $186M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new TARO positions and 9 closed out — a net gain of 11 holders — while 23 added to existing stakes and 23 trimmed.

The largest buyer was Invesco, opening a new position worth an estimated $9.95M. The largest seller was Acadian Asset Management, cutting an estimated $9.32M.

  • 82 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q3 2023, up from 71 in Q2 2023.
  • Funds reported $185M of Taro Pharmaceutical Industries Ltd. stock for Q3 2023, down 0.76% quarter-over-quarter.
  • 20 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q3 2023 and 9 closed out, a net change of +11 holders.
  • The largest Taro Pharmaceutical Industries Ltd. buyer in Q3 2023 was Invesco, an estimated $9.95M added.
  • The largest Taro Pharmaceutical Industries Ltd. seller in Q3 2023 was Acadian Asset Management, an estimated $9.32M sold.

Based on aggregated 13F filings for Q3 2023.